Conv. Plasma
Nigella Sativa

All quercetin studies
Meta analysis
study COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Symp. case 93% Improvement Relative Risk Quercetin  Rondanelli et al.  Prophylaxis  DB RCT Is prophylaxis with quercetin beneficial for COVID-19? Double-blind RCT 120 patients in Italy (January - May 2021) Fewer symptomatic cases with quercetin (p=0.042) Rondanelli et al., Life, January 2022 Favors quercetin Favors control

Promising Effects of 3-Month Period of Quercetin Phytosome® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study

Rondanelli et al., Life, doi:10.3390/life12010066, NCT05037240
Jan 2022  
  Source   PDF   All   Meta
Quercetin for COVID-19
22nd treatment shown to reduce risk in July 2021
*, now known with p = 0.0031 from 11 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
RCT 120 healthcare workers, 60 treated with quercetin phytosome, showing lower risk of cases with treatment. Quercetin phytosome 250mg twice a day.
This is the 6th of 10 COVID-19 RCTs for quercetin, which collectively show efficacy with p=0.0049.
This is the 7th of 11 COVID-19 controlled studies for quercetin, which collectively show efficacy with p=0.0031.
risk of symptomatic case, 92.9% lower, HR 0.07, p = 0.04, treatment 1 of 60 (1.7%), control 4 of 60 (6.7%), adjusted per study, inverted to make HR<1 favor treatment, Cox proportional risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rondanelli et al., 4 Jan 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Italy, peer-reviewed, 12 authors, study period 12 January, 2021 - 25 May, 2021, trial NCT05037240 (history).
This PaperQuercetinAll
Promising Effects of 3-Month Period of Quercetin Phytosome® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study
Mariangela Rondanelli, Simone Perna, Clara Gasparri, Giovanna Petrangolini, Pietro Allegrini, Alessandro Cavioni, Milena Anna Faliva, Francesca Mansueto, Zaira Patelli, Gabriella Peroni, Alice Tartara, Antonella Riva
Life, doi:10.3390/life12010066
Quercetin, for its crucial properties, fulfills the need for a multifactor action that is useful for the potential counterbalance of a COVID-19 infection. Given this background, the aim of the study was to evaluate the potential effect of 3 months' supplementation with Quercetin Phytosome ® (250 mg twice a day) as prevention against symptomatic COVID-19. In total, 120 subjects were enrolled (males, 63; females, 57; age 49 ± 12), with 60 in the supplementation group and 60 in the placebo group. No significant differences were detected between groups in terms of gender, smoking, and chronic disease. Subjects underwent rapid COVID-19 diagnostic tests every 3 weeks. During our study, 5 subjects had COVID-19, 1 out of 60 subjects in the quercetin group and 4 out of 60 in the control group. Complete clinical remission was recorded at 7 and 15 days in the quercetin and placebo groups, respectively. Analysis showed that, at 5 months, the COVID free survival function (risk of infection) was 99.8% in subjects under quercetin supplementation and 96.5% in control group. As shown by the value of EXP(B), those who had taken the supplement had a protection factor of 14% more to not contract the COVID-19 infection than that of those who had taken a placebo. Obtained results are encouraging, but further studies are required to add quercetin as regular prophylaxis.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the University (approval number: 1222/01022021). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Arslan, Ucuncu Ergun, Topuz, Yilmaz Semerci, Suner et al., Synergistic Effect of Quercetin and Vitamin C Against COVID-19: Is a Possible Guard for Front Liners, SSRN Electron. J, doi:10.2139/ssrn.3682517
Aucoin, Cooley, Saunders, Cardozo, Remy et al., The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review, Adv. Integr. Med, doi:10.1016/j.aimed.2020.07.007
Brendler, Al-Harrasi, Bauer, Gafner, Hardy et al., Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice, Phytother. Res, doi:10.1002/ptr.7008
Cesarone, Belcaro, Hu, Dugall, Hosoi et al., Supplementary prevention and management of asthma with quercetin phytosome: A pilot registry, Minerva Med, doi:10.23736/S0026-4806.19.06319-5
Derosa, Maffioli, D'angelo, Di Pierro, A role for quercetin in coronavirus disease 2019 (COVID-19), Phytother. Res, doi:10.1002/ptr.6887
Di Pede, Bresciani, Calani, Petrangolini, Riva et al., The human microbial metabolism of quercetin in different formulations: An in vitro evaluation, Foods, doi:10.3390/foods9081121
Di Pierro, Derosa, Maffioli, Bertuccioli, Togni et al., Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study, Int. J. Gen. Med, doi:10.2147/IJGM.S318720
Di Pierro, Iqtadar, Khan, Ullah Mumtaz, Masud Chaudhry et al., Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial, Int. J. Gen. Med, doi:10.2147/IJGM.S318949
Di Pierro, Khan, Bertuccioli, Maffioli, Derosa et al., Quercetin Phytosome®as a potential candidate for managing COVID-19, Minerva Gastroenterol, doi:10.23736/S2724-5985.20.02771-3
Dziadzko, Novotny, Sloan, Gajic, Herasevich et al., Multicenter derivation and validation of an early warning score for acute respiratory failure or death in the hospital, Crit. Care, doi:10.1186/s13054-018-2194-7
Glinsky, Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human, Biomedicines, doi:10.3390/biomedicines8050129
Gomes Da Silva, Fighting coronaviruses with natural polyphenols, Biocatal. Agric. Biotechnol, doi:10.1016/j.bcab.2021.102179
Gralinski, Baric, Molecular pathology of emerging coronavirus infections, J. Pathol, doi:10.1002/path.4454
Khaerunnisa, Kurniawan, Awaluddin, Suhartati, Soetjipto, Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study, Preprints
Lee, Yu, Trimpert, Benthani, Mairhofer et al., Virus-induced senescence is a driver and therapeutic target in COVID-19, Nature, doi:10.1038/s41586-021-03995-1
Li, Fan, Lai, Han, Li et al., Coronavirus infections and immune responses, J. Med. Virol, doi:10.1002/jmv.25685
Li, Geng, Peng, Meng, Lu, Molecular immune pathogenesis and diagnosis of COVID-19, J. Pharm. Anal, doi:10.1016/j.jpha.2020.03.001
Liu, Raghuvanshi, Ceylan, Bolling, Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity, J. Agric. Food Chem, doi:10.1021/acs.jafc.0c05064
Majumder, Minko, Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19, AAPS J
Margolin, Luchins, Margolin, Margolin, Lefkowitz, 20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment, J. Evid.-Based Integr. Med, doi:10.1177/2515690X211026193
Pawar, Pal, Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients, Phytother. Res, doi:10.1002/ptr.6886
Riva, Corti, Belcaro, Cesarone, Dugall et al., Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin, Minerva Cardioangiol, doi:10.23736/S0026-4725.18.04795-3
Riva, Ronchi, Petrangolini, Bosisio, Allegrini, Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin, Eur. J. Drug Metab. Pharmacokinet, doi:10.1007/s13318-018-0517-3
Riva, Vitale, Belcaro, Hu, Feragalli et al., Quercetin phytosome®in triathlon athletes: A pilot registry study, Minerva Med, doi:10.23736/S0026-4806.18.05681-1
Russo, Moccia, Spagnuolo, Tedesco, Russo, Roles of flavonoids against coronavirus infection, Chem. Biol. Interact, doi:10.1016/j.cbi.2020.109211
Shi, Wang, Shao, Huang, Gan et al., COVID-19 infection: The perspectives on immune responses, Cell Death Differ, doi:10.1038/s41418-020-0530-3
Smith, Prytherch, Meredith, Schmidt, Featherstone, The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death, Resuscitation, doi:10.1016/j.resuscitation.2012.12.016
Smith, Smith, Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop